Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liang Zeng

Showing results (611-620 of 633) with videos related to

Pageof 64
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 8, 2022
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangementsYuxiang Ma, Hongyun Zhao, Jinhui Xue, et al.
Med (New York, N.Y.)|February 1, 2025
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trialLiang Zeng, Huan Yan, Wenjuan Jiang, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2024
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in ChinaHuan Yan, Lianxi Song, Yizhi Li, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2024
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective studyZhe Huang, Yuda Zhang, Qinqin Xu, et al.
Cancer Letters|January 12, 2025
RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIsXinjun Tang, Jie Hu, Renhua Guo, et al.
Plos One|September 2, 2015
Prion Protein Protects against Renal Ischemia/Reperfusion InjuryBo Zhang, Daniel Cowden, Fan Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2025
NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancerLinrui Ma, Xiangyu Zhang, Shidong Xu, et al.
Nature Medicine|February 2, 2026
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trialZhe Huang, Liang Zeng, Zhaohui Ruan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 2, 2025
Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancerLiang Zeng, Fan Tong, Xingxiang Xu, et al.
Cell Discovery|September 8, 2021
RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primatesXiaoyan Pan, Jian Shi, Xue Hu, et al.
Pageof 64

Showing results (611-620 of 633) with videos related to

Sort By:
Pageof 64
European Journal of Cancer (Oxford, England : 1990)|August 8, 2022
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangementsYuxiang Ma, Hongyun Zhao, Jinhui Xue, et al.
Med (New York, N.Y.)|February 1, 2025
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trialLiang Zeng, Huan Yan, Wenjuan Jiang, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2024
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in ChinaHuan Yan, Lianxi Song, Yizhi Li, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2024
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective studyZhe Huang, Yuda Zhang, Qinqin Xu, et al.
Cancer Letters|January 12, 2025
RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIsXinjun Tang, Jie Hu, Renhua Guo, et al.
Plos One|September 2, 2015
Prion Protein Protects against Renal Ischemia/Reperfusion InjuryBo Zhang, Daniel Cowden, Fan Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2025
NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancerLinrui Ma, Xiangyu Zhang, Shidong Xu, et al.
Nature Medicine|February 2, 2026
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trialZhe Huang, Liang Zeng, Zhaohui Ruan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 2, 2025
Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancerLiang Zeng, Fan Tong, Xingxiang Xu, et al.
Cell Discovery|September 8, 2021
RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primatesXiaoyan Pan, Jian Shi, Xue Hu, et al.
Pageof 64